Sorrento Therapeutics Archives

Sorrento Therapeutics Receives Approval for $75MM DIP Financing from JMB Capital Partners

The U.S. Bankruptcy Court for the Southern District of Texas granted final approval of Sorrento Therapeutics’ $75 million debtor-in-possession financing from JMB Capital Partners in connection with Sorrento’s Chapter 11 bankruptcy filing in February.

Oaktree Provides $150MM Term Loan to Sorrento Therapeutics

Sorrento Therapeutics, a clinical-stage immunotherapy biotech company, closed a debt financing for up to $150 million. The financing was provided by funds and accounts managed by Oaktree Capital Management.

November 8, 2018 Morgan Stanley | Oaktree Capital Management | Sorrento Therapeutics Amanda Koprowski

Hercules Provides $75MM Sorrento Therapeutics Facility

Sorrento Therapeutics, a clinical-stage biopharmaceutical company developing treatments for cancer and other diseases, entered into a loan and security agreement with Hercules Capital for up to $75 million.

November 29, 2016 Hercules Capital | Kevin Herde | Scott Bluestein | Sorrento Therapeutics ABF Journal

Oxford/SVB Expand Term Loan with Sorrento Therapeutics

Oxford Finance and Silicon Valley Bank announced a $7.5 million expansion to an existing $5 million term loan with Sorrento Therapeutics.

April 17, 2014 Oxford Finance | Silicon Valley Bank | Sorrento Therapeutics ABF Journal

<img width="200" src="https://www.abfjournal.com/wp-content/uploads/2020/02/abfj-logo-web-header1-blue.png" alt="ABFJournal" />

Tag Archives: Sorrento Therapeutics

Sorrento Therapeutics Receives Approval for $75MM DIP Financing from JMB Capital Partners

Oaktree Provides $150MM Term Loan to Sorrento Therapeutics

Hercules Provides $75MM Sorrento Therapeutics Facility

Oxford/SVB Expand Term Loan with Sorrento Therapeutics